Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00848627 · ClinicalTrials.gov registry record
Screening for Bladder Cancer
A clinical trial of Bladder Cancer, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- 197
- Enrollment target
- 3
- Study locations
NCT00848627 is a study of Bladder Cancer that has completed, run by Baylor College of Medicine. The registered enrollment target is 197 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00848627, a study of Bladder Cancer, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- 197 participants
- Enrollment target
- 3
- Study locations
Study Summary
In the study proposed, up to 1,500 men age 60 and over with strong smoking histories will test their urine for the presence of blood daily for two 10-day testing periods with the Ames Hemastix. Individuals with even a solitary positive test will undergo a thorough urologic evaluation to determine the cause of hematuria and follow-up will continue for 2 years after completion of the study.
Conditions Studied
Interventions
- OTHER Specimen and questionnaires only
Study Locations (3)
New York
- University of Rochester Medical Center - Rochester
Texas
- M.D. Anderson Cancer Center - Houston
Quebec
- Laval University - Québec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2007-03 |
| Est. Completion | 2012-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00848627
The ClinicalTrials.gov registry entry for NCT00848627 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Specimen and questionnaires only is the first listed.
NCT00848627 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, Texas, Quebec.
Frequently Asked Questions
What is clinical trial NCT00848627 about?
NCT00848627 is a clinical study titled "Screening for Bladder Cancer". In the study proposed, up to 1,500 men age 60 and over with strong smoking histories will test their urine for the presence of blood daily for two 10-day testing periods with the Ames Hemastix. Individuals with even a solitary positive test will undergo a thorough urologic evaluation to determine th...
What is the current status of trial NCT00848627?
This trial is currently completed. The enrollment target is 197 participants. The study started on 2007-03. Estimated completion is 2012-02.
What conditions does trial NCT00848627 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT00848627?
The interventions under investigation include: Specimen and questionnaires only (OTHER).
Who is sponsoring clinical trial NCT00848627?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00848627 being conducted?
This trial has 3 study locations across New York, Texas, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.